The Neuro Partnerships Program envelope of $3.1 million is available until 2023. Under this program, Healthy Brains, Healthy Lives (HBHL) provides 1:1 matching funds for projects with a high potential impact on biopharmaceutical research through existing programs offered by the Ministère de l'Économie et de l'Innovation (). Co-funding is available for up to 40% of the total project cost. MEI co-funding is available through Quantum Leap and SynergiQc programs; and the Industrial Consortium for Research and Innovation in Medical Technologies. Read more about this program and the evaluation process.
Theme | Principal Investigator | MEI partnerÌý | Other partners | Project title |
Funding received |
---|---|---|---|---|---|
2 |
Philippe Séguéla |
CQDM-SynergiQc |
Neurasic Therapeutics The Jewish Community Foundation of Montreal Mitacs |
Discovery of Analgesic Drugs Targeting the Acid-Sensing Ion Channel Family. |
Total: $1,035,505 HBHL: $200,000 |
3 |
Etienne de Villers Sidani |
MEDTEQ-Impact |
PhysioBiometrics Mitacs |
Promoting BEST (BEtter, Faster, Longer, STronger) Walking for People with Parkinsons |
Total: $282,477 HBHL: $66,276 |
3 |
Rosemary Bagot |
CQDM-SynergiQc |
Cubed Biotech Ludmer Family Foundation |
Revealing the neural circuit mechanisms of psilocybin in a depression-relevant brain circuit |
Total: $525,000 HBHL: $200,000 |
1 |
Blake Richards |
MEDTEQ-Impact |
BIOS Santé Mitacs |
Closed loop AI-controlled neural stimulation for treating chronic conditions |
Total: $903,585 HBHL: $129,500 |
3 |
Jeremy Cooperstock |
MEDTEQ-Impact |
Haply Robotics |
Kinesthetic interaction device and multimodal authoring tool to support audio-haptic rendering of graphical content for blind and low-vision users Ìý |
Total: $262,467 HBHL: $56,438 |
2 | Brian Chen | CQDM-Quantum Leap |
The Research Institute of the À¦°óSMÉçÇø Health Centre (RI-MUHC) Brain Canada |
A drug-screening platform to increase protein expression levels for the treatment of neurological disorders. |
Total: $1,495,789 HBHL: $580,000 |
2 | Philippe Gros | CQDM-SynergiQc |
Corbin Therapeutics Brain Canada |
Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs. |
Total: $1,582,821 HBHL: $550,000 |
3 | Alain Ptito | MEDTEQ-Impact |
Saccade Analytics Fondation NeuroTrauma Marie-Robert Mitacs |
Advanced Nystagmus System (ANSâ„¢) as objective diagnostic tool for mild traumatic brain injury (mTBI) and concussion: A validation study using structural and functional magnetic resonance imaging. |
Total: $216,377 HBHL: $51,322 |
2 | Jean-Paul Soucy | MEDTEQ-Impact |
Optina Diagnostics Mitacs Collaborative Health Research Projects |
Evaluation of a radiomic approach based on hyperspectral retinal imaging to predict the cerebral amyloid status for the diagnosis of Alzheimer’s disease. |
Total: $881,578 HBHL: $208,757 |
1 | Manuela Ferrari (previously, Outi Linnaranta) | MEDTEQ-Impact |
Aifred Health Douglas Hospital |
Implementation of a digital mental health tool in an Urban and Rural Setting – Optimizing Usability and Data Quality. |
Total: $88,104 HBHL: $21,000 |
1 | Yasser Iturria-Medina | MEDTEQ-Impact |
Arctic Fox AI MGH Foundation |
Data-driven Biomarker Based Alzheimer’s Disease Progression Composite Score. |
Total: $120,498 HBHL: $42,000 |
2 | David Juncker | CQDM-Quantum Leap | Nplex Biosciences | The 200-plex nano-ELISA: a next-generation immuno-proteomic technology for biomarker and drug discovery. |
Total: $845,484 HBHL: $200,000 |
2 | Thomas Durcan | CQDM-Quantum Leap | Brain Canada | Development of a high throughput 3D microphysiological platform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders. |
Total: $1,755,736 HBHL: $600,000 |
1 | Blake Richards | MEDTEQ-Impact |
Mitacs Bios Santé |
Development of an AI-controlled closed-loop neuromodulation system for chronic conditions |
Total: $392,647 HBHL: |
2 | Thomas Durcan | CQDM-SynergiQc |
Raya Therapeutique Eikonizo Therapeutics |
The preclinical development of 5 molecules for Amyotrophic Lateral Sclerosis and other neurodegenerative |
Total: $1,938,890 HBHL: $200,000 |